Tumor Necrosis Factor-regulated Biphasic Activation of NF-kappa B is Required for Cytokine-induced Loss of Skeletal Muscle Gene Products
Overview
Affiliations
NF-kappaB activation is classically defined as a transient response initiated by the degradation of IkappaB inhibitor proteins leading to nuclear import of NF-kappaB and culminating with the resynthesis of IkappaBalpha and subsequent inactivation of the transcription factor. Although this type of regulation is considered the paradigm for NF-kappaB activation, other regulatory profiles are known to exist. By far the most common of these is chronic or persistent activation of NF-kappaB. In comparison, regulation of NF-kappaB in a biphasic manner represents a profile that is scarcely documented and whose biological significance remains poorly understood. Here we show using differentiated skeletal muscle cells, that tumor necrosis factor (TNF) induces NF-kappaB activation in a biphasic manner. Unlike the first transient phase, which is terminated within 1 h of cytokine addition, the second phase persists for an additional 24-36 h. Biphasic activation is mediated at both the levels of NF-kappaB DNA binding and transactivation function, and both phases are dependent on the IKK/26 S proteasome pathway. We find that regulation of the first transient phase is mediated by the degradation and subsequent resynthesis of IkappaBalpha, as well as by a TNF-induced expression of A20. Second phase activity correlates with persistent down-regulation of both IkappaBalpha and IkappaBbeta proteins, derived from a continuous TNF signal. Finally, we demonstrate that inhibition of NF-kappaB prior to initiation of the second phase of activity inhibits cytokine-mediated loss of muscle proteins. We propose that the biphasic activation of NF-kappaB in response to TNF may play a key regulatory role in skeletal muscle wasting associated with cachexia.
Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting.
Nevi L, Pollanen N, Penna F, Caretti G Int J Mol Sci. 2023; 24(22).
PMID: 38003594 PMC: 10671811. DOI: 10.3390/ijms242216404.
Role of Brain Liver X Receptor in Parkinson's Disease: Hidden Treasure and Emerging Opportunities.
Alnaaim S, Al-Kuraishy H, Alexiou A, Papadakis M, Saad H, El-Saber Batiha G Mol Neurobiol. 2023; 61(1):341-357.
PMID: 37606719 PMC: 10791998. DOI: 10.1007/s12035-023-03561-y.
Alrouji M, Al-Kuraishy H, Al-Gareeb A, Alexiou A, Papadakis M, Jabir M J Cell Mol Med. 2023; 27(13):1775-1789.
PMID: 37210624 PMC: 10315781. DOI: 10.1111/jcmm.17784.
Parkinson's Disease Risk and Hyperhomocysteinemia: The Possible Link.
Al-Kuraishy H, Al-Gareeb A, Elewa Y, Zahran M, Alexiou A, Papadakis M Cell Mol Neurobiol. 2023; 43(6):2743-2759.
PMID: 37074484 PMC: 10333143. DOI: 10.1007/s10571-023-01350-8.
Di Credico A, Gaggi G, Izzicupo P, Vitucci D, Buono P, Di Baldassarre A J Histochem Cytochem. 2023; 71(4):199-209.
PMID: 37013268 PMC: 10149894. DOI: 10.1369/00221554231165326.